Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Marilyn K. Glassberg; Steven D. Nathan; Chin Yu Lin; Elizabeth A. Morgenthien; John L. Stauffer; Willis Chou; Paul W. Noble

doi:10.1007/s12325-019-01082-6

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Marilyn K. Glassberg
, Steven D. Nathan
, Chin Yu Lin
, Elizabeth A. Morgenthien
, John L. Stauffer
, Willis Chou
, Paul W. Noble

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

Original language	English (US)
Pages (from-to)	2927-2929
Number of pages	3
Journal	Advances in Therapy
Volume	36
Issue number	10
DOIs	https://doi.org/10.1007/s12325-019-01082-6
State	Published - Oct 1 2019
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s12325-019-01082-6

Fingerprint

Dive into the research topics of 'Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)'. Together they form a unique fingerprint.

Cite this

Glassberg, M. K., Nathan, S. D., Lin, C. Y., Morgenthien, E. A., Stauffer, J. L., Chou, W., & Noble, P. W. (2019). Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y). Advances in Therapy, 36(10), 2927-2929. https://doi.org/10.1007/s12325-019-01082-6

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y). / Glassberg, Marilyn K.; Nathan, Steven D.; Lin, Chin Yu et al.
In: Advances in Therapy, Vol. 36, No. 10, 01.10.2019, p. 2927-2929.

Research output: Contribution to journal › Comment/debate › peer-review

Glassberg, MK, Nathan, SD, Lin, CY, Morgenthien, EA, Stauffer, JL, Chou, W & Noble, PW 2019, 'Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)', Advances in Therapy, vol. 36, no. 10, pp. 2927-2929. https://doi.org/10.1007/s12325-019-01082-6

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W et al. Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y). Advances in Therapy. 2019 Oct 1;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6

@article{124e839db3a94a95915df8aa36d399e9,

title = "Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)",

abstract = "In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.",

author = "Glassberg, \{Marilyn K.\} and Nathan, \{Steven D.\} and Lin, \{Chin Yu\} and Morgenthien, \{Elizabeth A.\} and Stauffer, \{John L.\} and Willis Chou and Noble, \{Paul W.\}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = oct,

day = "1",

doi = "10.1007/s12325-019-01082-6",

language = "English (US)",

volume = "36",

pages = "2927--2929",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "10",

}

TY - JOUR

T1 - Correction to

T2 - Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

AU - Glassberg, Marilyn K.

AU - Nathan, Steven D.

AU - Lin, Chin Yu

AU - Morgenthien, Elizabeth A.

AU - Stauffer, John L.

AU - Chou, Willis

AU - Noble, Paul W.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

AB - In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

UR - https://www.scopus.com/pages/publications/85072992535

UR - https://www.scopus.com/pages/publications/85072992535#tab=citedBy

U2 - 10.1007/s12325-019-01082-6

DO - 10.1007/s12325-019-01082-6

M3 - Comment/debate

C2 - 31502216

AN - SCOPUS:85072992535

SN - 0741-238X

VL - 36

SP - 2927

EP - 2929

JO - Advances in Therapy

JF - Advances in Therapy

IS - 10

ER -

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this